A Plus Biotechnology Co EBIT

A Plus Biotechnology Co's ebit stands at $200M as of March 2026. That compares with $200M in the prior-year period — up 1.6% year over year. That is below the sector sector average of $2.5T. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

A Plus Biotechnology Co reported $200M in EBIT versus $200M a year earlier — a 1.6% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

A Plus Biotechnology Co sits lower the its sector benchmark ($2.5T) with a EBIT of $200M. That is roughly 100.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $200M in the prior-year period — up 1.6% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how A Plus Biotechnology Co's EBIT evolved across reporting periods, while the comparison chart places 6918.TW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.